Repligen Corp
RGEN
查看详细走势图
157.390USD
-4.270-2.64%
收盘 12/12, 16:00（美东）报价延迟15分钟
8.86B总市值
5641.22市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.64%
5天
-4.60%
1月
-0.39%
6月
+19.87%
今年开始到现在
+9.34%
1年
+0.90%
查看详细走势图
TradingKey Repligen Corp股票评分
单位: USD 更新时间: 2025-12-12操作建议
Repligen Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名19/208位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价187.96。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Repligen Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
22
位分析师
买入
评级
187.959
目标均价
+16.88%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Repligen Corp亮点
亮点风险
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值5641.22，处于3年历史高位
机构减仓
最新机构持股55.23M股，环比减少10.18%
加拿大丰业银行分红基金持仓
明星投资者加拿大丰业银行分红基金持仓，最新持仓市值40.66K
Repligen Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Repligen Corp简介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代码RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
网址https://www.repligen.com/
常见问题
Repligen Corp(RGEN)的当前股价是多少？
Repligen Corp(RGEN)的当前股价是 157.390。
Repligen Corp的股票代码是什么？
Repligen Corp的股票代码是RGEN。
Repligen Corp股票的52周最高点是多少？
Repligen Corp股票的52周最高点是182.520。
Repligen Corp股票的52周最低点是多少？
Repligen Corp股票的52周最低点是102.965。
Repligen Corp的市值是多少？
Repligen Corp的市值是8.86B。
Repligen Corp的净利润是多少？
Repligen Corp的净利润为-25.51M。
现在Repligen Corp(RGEN)的股票是买入、持有还是卖出？
根据分析师评级，Repligen Corp(RGEN)的总体评级为买入，目标价格为187.959。
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是多少
Repligen Corp(RGEN)股票的每股收益（EPS TTM）是0.028。
相关品种
+1.52%
+1.77%
-1.14%
-0.92%
-2.60%
+0.90%
+0.32%
+0.12%
+0.50%
-1.74%
-0.32%
+0.90%
+0.44%
+0.23%
-0.47%
-1.38%
-2.23%
+0.05%
-2.43%
-0.05%
